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Background: The number of N2 stations (single vs multiple N2 stations) is an
important prognostic factor in patients with completely resected stage IIIA-N2
non–small cell lung cancer. However, the significance of both the N2 station(s)
actually involved and the primary tumor location remains unclear. 
Methods: The database was built with the use of a questionnaire survey on the sur-
vival of patients with pathologic stage IIIA-N2 non–small cell lung cancer com-
pletely resected between January 1992 and December 1993. The survey was
performed by the Japan Clinical Oncology Group as of July 1999. The data include
information on the survival and N2 stations of 402 patients.
Results: A frequently metastasized single N2 station was the lower pretracheal sta-
tion in primary tumors in the right upper lobe, the subaortic station in the left upper
lobe, and the subcarinal station in the right middle or lower lobe and the left lower
lobe. In multiple N2 stations, the frequency of metastasis of the N2 station observed
in a single N2 station was as high as 72% to 89%, and one or two other frequently
metastasized stations were added to each group. Regarding the survival of patients
with a primary tumor in each lobe except for the left lower lobe, a single N2 station
resulted in a significantly better survival than did multiple N2 stations. Furthermore,
the overall survivals classified according to each primary site showed a significant
difference among the four primary sites (P = .04).
Conclusions: The primary tumors in each lobe showed a prevalence of N2 sta-
tion(s). The number of N2 stations is a good prognosticator except in patients with
a primary tumor in the left lower lobe. In addition, the site of a primary tumor itself
is also considered to influence the survival of the patients. 
Survival of patients with stage IIIA-N2 disease is known to be variable.Even if the subjects are limited to patients with completely resectedpathologic stage IIIA-N2 non–small cell lung cancer (NSCLC), thatsituation does not change. Therefore, extensive clinical research hasbeen done to elucidate the prognostic factors that are useful for identi-fying a homogeneous survival subgroup among patients undergoing
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resection. The prognostic factors1-7 identified so far are the
pathologic characteristics of the tumor, the extent of the
primary tumor, the clinical N status, the number of N2 sta-
tions, the presence of subcarinal N2 disease, the extracap-
sular spread in N2 disease, and the extent of the resection.
Among these prognostic factors, the number of N2 stations
(single vs multiple) has been recognized as one of the most
important.1,6 In our previous study using the same subjects
as in the present study, the number of N2 stations was also
found to be the most important prognostic factor on the
basis of a multivariate analysis.8 To our knowledge, how-
ever, the site of N2 station(s) actually involved when com-
paring a single N2 station with multiple N2 stations has not
been reported. In addition, whether the importance of the
number of N2 stations as a prognostic factor is influenced
by the location of the primary tumor remains to be eluci-
dated. In the present study, we therefore attempted to clarify
these issues.
Patients and Methods
Subjects 
Patients with NSCLC and pathologic stage IIIA-N2 disease com-
pletely resected by either a lobectomy or a pneumonectomy from
January 1992 to December 1993 who did not receive preoperative
chemotherapy or radiotherapy were the subjects of a questionnaire
survey on survival. The survey was conducted by the Lung Cancer
Surgical Study Group of the Japan Clinical Oncology Group
(JCOG) as of July 1999. The data included information on the sur-
vival and the involved N2 station(s) from 406 patients.8 All patients
underwent computed tomographic scanning of the chest, but medi-
astinoscopy was not routinely used. Four patients were excluded
from the present study because the primary tumor was located in
only the main bronchus or the truncus intermedius. The character-
istics of all 402 patients are shown in Table 1.
Location of the Mediastinal Lymph Nodes 
The location of the dissected mediastinal lymph nodes was
described according to the lymph node map for lung cancer pro-
posed by Naruke and associates7: station 1, highest mediastinal sta-
tion; station 2, paratracheal station; station 3, (lower) pretracheal
station; station 3a, anterior mediastinal station; station 3p, retrotra-
cheal station; station 4, tracheobronchial station; station 5, subaor-
tic station; station 6, para-aortic (ascending aorta) station; station 7,
subcarinal station; station 8, paraesophageal station; and station 9,
pulmonary ligament station. The N2 stations were analyzed accord-
ing to the lobe in which the primary tumor was located.
Survival and Local Recurrence 
The overall survival was defined as the time from the operation
until death from any cause. Survival curves were drawn by means
of the Kaplan-Meier method and a statistical evaluation of the
curves was done by means of a log-rank test.
Results
General 
The 3- and 5-year survivals of all 402 patients were 42%
(95% confidence interval [CI]: 37%-47%) and 31% (95%
CI: 26%-35%), respectively. The 3- and 5-year survivals of
the 209 patients with a single N2 station were 51% (95% CI:
44%–58%) and 43% (95% CI: 36%–49%), whereas those of
the 193 patients with multiple N2 stations were 32% (95%
CI: 25%–39%) and 17% (95% CI: 12%–22%), respectively.
The survival of patients with a single N2 station was signif-
icantly better than that of patients with multiple N2 stations
(P < .0001). 
Right Upper Lobe (Table 2 and Figure 1) 
A frequently metastasized N2 station was station 3 in
patients with a single N2 station and stations 1, 3, and 4 in
patients with multiple N2 stations. Although the frequency
of station 7 involvement was as low as 3% in patients with a
single N2 station, it reached as high as 30% in patients with
multiple N2 stations.
The 3- and 5-year survivals were 67% (95% CI: 55%–79%)
and 60% (95% CI: 48%–73%) in the 59 patients with a single
N2 station, whereas the same survival figures were 28% (95%
CI: 16%–40%) and 23% (95% CI: 12%–35%), respectively, in
the 56 patients with multiple N2 stations (P < .0001).
TABLE 1. Patient characteristics (n = 402) 
Age (y)
Mean (range) 63 (35-82)
Sex
Male 287 (71%)
Female 115 (29%)
Histologic type
Adenocarcinoma 268 (67%)
Squamous cell carcinoma 100 (25%)
Others 34 (8%)
Pathologic T status
T1 126 (31%)
T2 229 (57%)
T3 47 (12%)
Tumor location
Right upper lobe 115 (29%)
Right middle lobe 18 (4%)
Right lower lobe* 100 (25%)
Left upper lobe 110 (27%)
Left lower lobe 59 (15%)
Operative modality
Pneumonectomy 46 (11%)
Bilobectomy 33 (8%)
Lobectomy 323 (80%)
Postoperative chemotherapy
None 239 (60%)
Done 163 (41%)
Postoperative radiotherapy
None 341 (85%)
Done 61 (15%)
*Two patients had tumor invasion of the right middle lobe.
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Right Middle or Lower Lobe (Table 3 and Figure 2) 
A frequently metastasized N2 station was station 7 in
patients with a single N2 station and stations 3 and 7 in
patients with multiple N2 stations. Although the frequency
of station 1 involvement was only 2% in patients with a sin-
gle N2 station, that increased to 39% in those with multiple
N2 stations.
The 3- and 5-year survivals were 42% (95% CI:
30%–55%) and 37% (95% CI: 25%–49%) in the 61 patients
with a single N2 station, and they were 33% (95% CI:
20%–45%) and 9% (95% CI: 1%–16%), respectively, in the
57 patients with multiple N2 stations (P = .0046).
Left Upper Lobe (Table 4 and Figure 3) 
A frequently metastasized N2 station was station 5 in patients
with a single N2 station and stations 4, 5, and 6 in patients with
multiple N2 stations. Although no involvement was observed
in the superior mediastinal N2 stations, including stations 1 to
3 in patients with a single N2 station, the frequency of involve-
ment in stations 1 plus 2 and station 3 increased to 10% and
37% in those with multiple N2 stations, respectively. 
The 3- and 5-year survivals were 49% (95% CI:
36%–62%) and 41% (95% CI: 28%–55%) in the 59 patients
with a single N2 station, whereas the same figures were
36% (95% CI: 22%–49%) and 16% (95% CI: 5%–27%) in
the 51 patients with multiple N2 stations, respectively (P =
0.0082). 
Left Lower Lobe (Table 5 and Figure 4) 
A frequently metastasized N2 station was station 7 in
patients with a single N2 station and stations 5 and 7 in
patients with multiple N2 stations.
The 3- and 5-year survivals were 41% (95% CI:
23%–59%) and 22% (95% CI: 7%–38%) in the 30 patients
with a single N2 station, whereas the same survivals were
35% (95% CI: 17%–54%) and 25% (95% CI: 7%–43%) in
the 29 patients with multiple N2 stations, respectively (P =
.7361).
TABLE 2. Prevalent N2 station(s) in patients with a primary
tumor in the right upper lobe
No. (%)
Station of mediastinal Single N2 station Multiple N2 stations 
lymph node (n = 59) (n = 56)
1 5 (9%) 30 (54%)*
2 3 (5%) 24 (43%)
3 32 (54%)* 50 (89%)*
3a 3 (5%) 10 (18%)
3p 0 2 (4%)
4 14 (23%) 36 (64%)*
7 2 (3%) 17 (30%)
8 0 0
9 0 2 (4%)
Total 59 171
*Frequently metastasized stations.
Figure 1. Survival curves of patients with a primary tumor in the
right upper lobe. Each bar represents a 95% confidence interval of
the survival. 
Figure 2. Survival curves of patients with a primary tumor in the
right middle or lower lobe. Each bar represents a 95% confidence
interval of the survival.
TABLE 3. Prevalent N2 station(s) in patients with a primary
tumor in the right middle or lower lobe
No. (%)
Station of mediastinal Single N2 station Multiple N2 stations 
lymph node (n = 61) (n = 57)
1 1 (2%) 22 (39%)
2 4 (7%) 14 (25%)
3 10 (16%) 39 (68%)*
3a 0 7 (12%)
3p 0 4 (7%)
4 3 (5%) 26 (46%)
7 38 (62%)* 49 (86%)*
8 4 (7%) 12 (21%)
9 1 (2%) 5 (9%)
Total 61 178
*Frequently metastasized stations.
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Comparison of Survival Between Primary Sites (Figure 5) 
The 5-year survival was 43% (95% CI: 33%-52%) in
patients with a primary tumor in the right upper lobe, 23%
(95% CI: 16%-31%) in the right middle or lower lobe, 30%
(95% CI: 21%-39%) in the left upper lobe, and 23% (95%
CI: 12%-35%) in the left lower lobe. A statistically signifi-
cantly difference in survival was observed among the four
primary sites (P = .0378). The prognosis was not influenced
by the side of the primary tumor (P = .2969); the 5-year sur-
vival was 33% (95% CI: 26%-39%) in right-sided tumors
and 28% (95% CI: 21%-35%) in left-sided tumors.
Discussion
The prevalent location of the metastasized mediastinal
lymph nodes in patients with stage IIIA-N2 disease has been
reported to be the superior mediastinal nodes (especially
station 3 or 4) in cancer of the right upper lobe, the subaor-
tic nodes (station 5) in cancer of the left upper lobe, and the
subcarinal nodes (station 7) in cancer of both the right mid-
dle and lower lobes and the left lower lobe.9,10 The most fre-
quently metastasized nodes are considered to be the medi-
astinal nodes nearest to the primary tumor along the medi-
astinal lymphatic drainage route.11 In patients with multiple
N2 stations, however, metastasized nodes located along
either an uncommon lymphatic drainage route or the lym-
phatic drainage route far from the primary tumor are fre-
quently observed, and the present study clearly
demonstrated this phenomenon. The metastasized subcari-
nal nodes observed in 30% of the patients with a tumor in
the right upper lobe and in 26% of those in the left upper
lobe, and the metastasized subaortic nodes in 59% of those
in the left lower lobe, represent the former case. The metas-
tasized highest mediastinal nodes (station 1) observed in
54% of the patients with tumor in the right upper lobe and
the metastasized lower pretracheal nodes (station 3) in 68%
of those in the right middle or lower lobe represent the nodal
involvement along the lymphatic drainage route far from the
primary tumor.
The relatively high frequency of skip mediastinal lymph
node metastasis, in which the affected lymph nodes were
not in the prevalent location for metastasis, in patients with
a single N2 station was an interesting finding in this study.
In particular, in cancer of the right middle or lower lobe and
of the left lower lobe, 30% of the patients with a single N2
station had metastasis to abnormal sites: to the right-sided
superior mediastinal nodes, including stations 1 to 4, and to
the left-sided nodes, including stations 4 to 6, respectively.
Takizawa,9 Riquet,12 and their associates reported that
among the dissected lymph nodes that were determined to
have metastasis on the basis of a postoperative pathologic
examination, 68% and 20% of these nodes, respectively,
were judged to have no metastasis according to intraopera-
tive macroscopic examinations. On the basis of the above
TABLE 4. Prevalent N2 station(s) in patients with a primary
tumor in the left upper lobe
No. (%)
Station of mediastinal Single N2 station Multiple N2 stations 
lymph node (n = 59) (n = 51)
1 0 1 (2%)
2 0 4 (8%)
3 0 19 (37%)
3a 0 6 (12%)
3p 0 0
4 7 (12%) 26 (51%)*
5 36 (61%)* 40 (78%)*
6 11 (19%) 26 (51%)*
7 5 (9%) 13 (26%)
8 0 2 (4%)
9 0 1 (2%)
Total 59 138
*Frequently metastasized stations.
Figure 3. Survival curves of patients with a primary tumor in the
left upper lobe. Each bar represents a 95% confidence interval of
the survival.
Figure 4. Survival curves of patients with a primary tumor in the
left lower lobe. Each bar represents a 95% confidence interval of
the survival.
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findings and our present data, a systemic nodal dissection is
thus thought to be necessary, not only to obtain a precise
staging of the disease but also to eradicate the intrathoracic
disease.
The present study demonstrated that the number of N2
stations (single vs multiple N2 stations) is an important
prognostic factor in patients with a primary tumor in the
right lung and the left upper lobe but not in the left lower
lobe. However, at the same time, the prognosis of patients
with a single N2 and multiple N2 stations was demonstrated
to be influenced by the location of the primary tumor.
Among patients with a primary tumor in the right upper
lobe, the 5-year survival was 60% in patients with a single
N2 station and 23% in those with multiple N2 stations. On
the other hand, the 5-year survival among patients with a
primary tumor in the right middle or lower lobe was 37% in
patients with a single N2 station and 9% in those with mul-
tiple N2 stations.
To our knowledge, whether the location of the primary
tumor in patients with completely resected pathologic stage
IIIA-N2 NSCLC influences survival has yet to be eluci-
dated. In the present study, the prognosis of patients was
significantly different depending on which of the four pri-
mary sites was affected. The 5-year survival was 23% in
patients with a primary tumor in either the right middle and
lower lobes or the left lower lobe. This figure was worse
than the 43% survival in right upper lobe tumors or the 30%
survival in left upper lobe tumors. These observations indi-
cate that lung cancer in the lower lobe with N2 disease may
be more advanced than cancer in the upper lobe with N2 dis-
ease. 
Subcarinal lymph node metastasis, which is most fre-
quently observed among the metastasized mediastinal
lymph nodes of patients with cancer in the lower lobe
including the middle lobe, is thus reported to adversely
influence survival.7,13,14 However, these poor results may
reflect the poor prognosis of patients with cancer in the
lower lobe. In fact, the survival of patients with a single N2
station whose primary tumor was located in the middle or
lower lobes in the present study was not influenced by the
presence or absence of the subcarinal lymph node metasta-
sis: the 5-year survival of cancer in the right middle or lower
lobe was 36% (95% CI: 20%-51%) in the 38 patients with
subcarinal nodal involvement as a single N2 station and
34% (95% CI: 14%-53%) in the 23 patients with the nodal
involvement of the other sites as a single N2 station (P =
.3738; data not shown in the “Results”). In patients with
cancer in the left lower lobe, the 5-year survival was 22%
(95% CI: 1%-43%) in the 17 patients with the subcarinal
nodal involvement as a single N2 station and 23% (95% CI:
0%-46%) in the 13 patients with the nodal involvement of
the other sites as a single N2 station (P = .9064; data not
shown in the “Results”).
In conclusion, the number of N2 stations (single N2 vs
multiple N2 stations) and the location of the primary tumor
was found to influence the survival of patients with com-
pletely resected stage IIIA-N2 NSCLC. Therefore, these
factors should be included as a stratified factor in a prospec-
tive clinical trial of such patients.
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